Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | QPCT | Q16769 | 1/20 | 0.49 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19059415 | 0.82 | CYP3A4 (0.54) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL5512404 | 0.79 | QPCT (0.58) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL19059737 | 0.75 | CYP3A4 (0.60) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL18381410 | 0.74 | CYP3A4 (0.74) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17481127 | 0.74 | CYP3A4 (0.74) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL18381312 | 0.73 | CYP3A4 (0.64) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17481134 | 0.73 | CYP3A4 (0.78) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17483163 | 0.73 | CYP3A4 (0.78) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17481128 | 0.72 | CYP3A4 (0.82) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL18381229 | 0.72 | CYP3A4 (0.63) | CYP3A4CYP2D6TSHRCYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | ACE, ACE2, MCTS1 | CYP3A4 1728/4885CYP2D6 3023/4885TSHR 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.